Brief: Lantern Pharma To Present Data Highlighting The Anti-Tumor Potency Of Drug Candidate Lp-284
31/08/2023 13:39
Aug 31 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA TO PRESENT DATA HIGHLIGHTING THE ANTI-TUMOR
POTENCY OF DRUG CANDIDATE LP-284 IN NON-HODGKIN’S LYMPHOMAS AT
THE SOCIETY OF HEMATOLOGIC ONCOLOGY ANNUAL MEETING
* LANTERN PHARMA INC - LANTERN EXPECTS TO INITIATE PHASE 1
CLINICAL TRIALS FOR LP-284 DURING Q4 OF 2023
Source text for Eikon: ID:nBw4G9R10a
Further company coverage: LTRN.O
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments